A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer

Trial Profile

A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Feb 2017 Results (n=9) presented at the 2017 Genitourinary Cancers Symposium
    • 17 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2017.
    • 17 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top